Venetoclax TDM in Newly Diagnosed AML: Response and Outlook
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how the drug venetoclax works in people newly diagnosed with acute myeloid leukemia (AML). It helps doctors understand the right dose for better results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years or older.
- You have been newly diagnosed with AML (not a type called APL).
- You are starting or have started treatment with venetoclax plus azacitidine.
- You have not had any previous treatment for AML (except certain emergency therapies).
- You are not taking part in another clinical trial for a new drug.
- You agree to come for regular checkups and let researchers collect your health data.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adjusting chemotherapy based on early signs of leukemia can improve outcomes for people newly diagnosed with acute myeloid leukemia (AML). It might be a good fit if you are starting treatment and have a certain level of leukemia cells in your blood after a few days of therapy.
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
This trial studies whether adding venetoclax to standard induction chemotherapy (homoharringtonine plus cytarabine) can improve outcomes for people with newly diagnosed AML. It mainly looks at people who can safely receive intensive chemotherapy but have certain heart, kidney, or lung limits.
This trial tests adding venetoclax (a targeted pill) to strong chemotherapy for people with newly diagnosed AML. It is for those whose leukemia cells do not clear quickly enough after standard induction therapy, to see if the combination helps them achieve remission.
This study looks at how blood levels of the drug venetoclax relate to remission in adults with acute myeloid leukemia (AML) who cannot have standard intensive chemotherapy. It aims to help doctors dose the drug more effectively.
This trial tests a combination of oral venetoclax and injected azacitidine for adults who are newly diagnosed with acute myeloid leukemia (AML) and cannot have standard strong chemotherapy. The goal is to see how well this treatment works and what side effects it may cause.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.